Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue microarray technology in breast cancer HER2 diagnostics.

Kristof Egervari1, Zoltan Szollosi, Zoltan Nemes

  • 1Department Pathology, Medical and Health Science Center, University of Debrecen Nagyerdei krt, 98 H-4012 Debrecen, Hungary.

Pathology, Research and Practice
|February 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes.

Nature cancer·2026
Same author

X-linked hypophosphatemia and spinal cord compression: a systematic review and illustrative case.

Acta neurochirurgica·2026
Same author

[Kikuchi-Fujimoto disease : a differential diagnosis of febrile lymphadenopathy].

Revue medicale suisse·2026
Same author

Azacitidine-induced remission enables allogeneic transplantation in <i>TET2</i>/<i>BCOR</i>-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report.

Haematologica·2026
Same author

Neurons undergo IFNγ-driven persistent epigenetic shifts and synaptopathy in encephalitis.

Neuron·2025
Same author

Glioma mimicking a cystic infectious disease: A case report of multifocal, multicentric cystic glioblastoma.

Surgical neurology international·2025
Same journal

Cuproptosis-mediated metabolic-inflammatory coupling in hypertensive myocardial injury: Mechanistic insights and therapeutic perspectives.

Pathology, research and practice·2026
Same journal

COL6A3 drives tumor progression and predicts prognosis in cervical squamous cell carcinoma.

Pathology, research and practice·2026
Same journal

A novel oxygen-releasing bilayer delivery system for cell survival and peripheral nerve regeneration.

Pathology, research and practice·2026
Same journal

Autophagy modulation in ulcerative colitis with traditional Chinese medicine: A review.

Pathology, research and practice·2026
Same journal

Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications.

Pathology, research and practice·2026
Same journal

CBFβ-SMMHC in inv(16) AML: Fusion biology, RUNX1 dysregulation, and therapeutic targeting of a leukemogenic protein-protein interaction.

Pathology, research and practice·2026
See all related articles

Tissue microarrays (TMAs) offer a cost-effective and reliable method for HER2 testing in breast cancer. This approach enhances diagnostic accuracy and supports new research directions.

Area of Science:

  • Oncology
  • Pathology
  • Biotechnology

Background:

  • Tissue microarrays (TMAs) are valuable tools in medical research, reducing costs for immunohistochemical examinations (IHC) and fluorescence in situ hybridization (FISH).
  • Standardization and reliability are key benefits of TMAs in diagnostic and research settings.
  • HER2 testing is crucial for breast cancer diagnosis and treatment selection.

Purpose of the Study:

  • To assess the routine applicability of TMAs for HER2 testing in invasive breast cancer.
  • To compare the concordance of HER2 testing results obtained from TMAs versus conventional large tissue sections.
  • To evaluate the utility of TMAs for fluorescence in situ hybridization (FISH) in determining Herceptin therapy suitability.

Main Methods:

  • Construction of TMAs from 174 consecutive invasive breast cancer cases.

Related Experiment Videos

  • Performance of double HER2 immunohistochemical (IHC) analysis and FISH on TMAs.
  • Comparison of IHC data from TMAs with results from conventional large tissue sections.
  • FISH analysis on TMAs for Herceptin therapy suitability assessment.

    • Main Results:

    • High concordance rates were observed between TMA-based IHC and large section analysis for HER2-negative (94.5%/92.7%), HER2 2+ (85.7%/88.9%), and HER2 3+ (91.2%/90%) cases.
    • FISH performed on TMAs successfully determined Herceptin therapy suitability in all tested cases.
    • Discordant cases were further validated using FISH on large sections, confirming TMA reliability.

    Conclusions:

    • TMAs are a reliable, cost-effective, and standardized tool for HER2 testing in breast cancer, suitable for routine diagnostic work.
    • The application of TMAs in HER2 testing facilitates efficient FISH analysis, aiding in treatment decisions.
    • TMAs open new avenues for breast cancer research by enabling high-throughput analysis and investigation of unusual cases.